MG Pharma S.r.l announced its long-term partnership with Luqa Pharmaceuticals to commercialize BMG's products in Hong Kong and China. In a press release published in PR Newswire, the agreement's terms specifies that Luqa will "exclusively register and commercialize BMG's highly innovative dermatology, oral care and Cancer Support Therapy products."

Among the products included in the agreement are IaluXid, a unique, non-antibiotic, combination gel formulation treating skin infections;,GelX and GelX Xero, innovations in supportive care preventing and treating Oral Mucositis and Xerostomia; and Aftacure, treating aphthous ulcers and mouth lesions." The products are expected to be launched by 2015.

The said products have been particularly made to deal with the requirements of both physicians and patients in the developing Chinese market.

"We are pleased to enter into a partnership with Luqa Pharmaceuticals, a company with whom we share the vision and values. BMG's proven innovation capabilities complements Luqa's deep understanding of the evolving needs in China's healthcare market," Marco Mastrodonato, President and CEO of BMG Pharma S.r.l., said.

"This long-term partnership is a major milestone for BMG as it opens us the door to the most exciting healthcare market in the world," Mastrodonato added.